Editorial: Engineered immune cells in cancer immunotherapy (EICCI)
<p dir="ltr">Adoptive Cell Therapy (ACT) to treat cancer represents a rapidly evolving field. New approaches for the genetic engineering of immune effector cells with either a T cell receptor (TCR) or a chimeric antigen receptor (CAR) (Figure 1 Panels A and B, respectively) have led...
Saved in:
| Main Author: | |
|---|---|
| Other Authors: | , |
| Published: |
2022
|
| Subjects: | |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1864513519298281472 |
|---|---|
| author | Francisco Martin (26407) |
| author2 | Axel Schambach (214256) Cristina Maccalli (2632465) |
| author2_role | author author |
| author_facet | Francisco Martin (26407) Axel Schambach (214256) Cristina Maccalli (2632465) |
| author_role | author |
| dc.creator.none.fl_str_mv | Francisco Martin (26407) Axel Schambach (214256) Cristina Maccalli (2632465) |
| dc.date.none.fl_str_mv | 2022-12-20T03:00:00Z |
| dc.identifier.none.fl_str_mv | 10.3389/fimmu.2022.1119363 |
| dc.relation.none.fl_str_mv | https://figshare.com/articles/journal_contribution/Editorial_Engineered_immune_cells_in_cancer_immunotherapy_EICCI_/25524025 |
| dc.rights.none.fl_str_mv | CC BY 4.0 info:eu-repo/semantics/openAccess |
| dc.subject.none.fl_str_mv | Biomedical and clinical sciences Immunology adoptive cell theraphy CAR-T cells TCR-engineered T cells tumor antigens mechanisms of resistance |
| dc.title.none.fl_str_mv | Editorial: Engineered immune cells in cancer immunotherapy (EICCI) |
| dc.type.none.fl_str_mv | Text Journal contribution info:eu-repo/semantics/publishedVersion text contribution to journal |
| description | <p dir="ltr">Adoptive Cell Therapy (ACT) to treat cancer represents a rapidly evolving field. New approaches for the genetic engineering of immune effector cells with either a T cell receptor (TCR) or a chimeric antigen receptor (CAR) (Figure 1 Panels A and B, respectively) have led to the increase of the clinical efficacy, the reduction or better control of toxicities and the expansion of the indications of these therapies. The Research Topic “Engineered Immune Cells in Cancer Immunotherapy (EICCI)” represents the venue for collecting studies, new evidence, advances in the technologies and the greatest knowledge for the translational application on the topic of cellular therapy for cancer. The great success of this Research Topic with the publication of total 46 articles, including 18 original articles, 20 reviews, 5 mini reviews, 2 case reports and 1 methodology manuscript, and the contributions of 360 authors, testify to the huge interest of the scientific community in this field and the numerous advancements.</p><h2>Other Information</h2><p dir="ltr">Published in: Frontiers in Immunology<br>License: <a href="https://creativecommons.org/licenses/by/4.0/" target="_blank">https://creativecommons.org/licenses/by/4.0/</a><br>See article on publisher's website: <a href="https://dx.doi.org/10.3389/fimmu.2022.1119363" target="_blank">https://dx.doi.org/10.3389/fimmu.2022.1119363</a></p> |
| eu_rights_str_mv | openAccess |
| id | Manara2_b8f1a358bb358bd1b8ddfc5f7c8ac27c |
| identifier_str_mv | 10.3389/fimmu.2022.1119363 |
| network_acronym_str | Manara2 |
| network_name_str | Manara2 |
| oai_identifier_str | oai:figshare.com:article/25524025 |
| publishDate | 2022 |
| repository.mail.fl_str_mv | |
| repository.name.fl_str_mv | |
| repository_id_str | |
| rights_invalid_str_mv | CC BY 4.0 |
| spelling | Editorial: Engineered immune cells in cancer immunotherapy (EICCI)Francisco Martin (26407)Axel Schambach (214256)Cristina Maccalli (2632465)Biomedical and clinical sciencesImmunologyadoptive cell theraphyCAR-T cellsTCR-engineered T cellstumor antigensmechanisms of resistance<p dir="ltr">Adoptive Cell Therapy (ACT) to treat cancer represents a rapidly evolving field. New approaches for the genetic engineering of immune effector cells with either a T cell receptor (TCR) or a chimeric antigen receptor (CAR) (Figure 1 Panels A and B, respectively) have led to the increase of the clinical efficacy, the reduction or better control of toxicities and the expansion of the indications of these therapies. The Research Topic “Engineered Immune Cells in Cancer Immunotherapy (EICCI)” represents the venue for collecting studies, new evidence, advances in the technologies and the greatest knowledge for the translational application on the topic of cellular therapy for cancer. The great success of this Research Topic with the publication of total 46 articles, including 18 original articles, 20 reviews, 5 mini reviews, 2 case reports and 1 methodology manuscript, and the contributions of 360 authors, testify to the huge interest of the scientific community in this field and the numerous advancements.</p><h2>Other Information</h2><p dir="ltr">Published in: Frontiers in Immunology<br>License: <a href="https://creativecommons.org/licenses/by/4.0/" target="_blank">https://creativecommons.org/licenses/by/4.0/</a><br>See article on publisher's website: <a href="https://dx.doi.org/10.3389/fimmu.2022.1119363" target="_blank">https://dx.doi.org/10.3389/fimmu.2022.1119363</a></p>2022-12-20T03:00:00ZTextJournal contributioninfo:eu-repo/semantics/publishedVersiontextcontribution to journal10.3389/fimmu.2022.1119363https://figshare.com/articles/journal_contribution/Editorial_Engineered_immune_cells_in_cancer_immunotherapy_EICCI_/25524025CC BY 4.0info:eu-repo/semantics/openAccessoai:figshare.com:article/255240252022-12-20T03:00:00Z |
| spellingShingle | Editorial: Engineered immune cells in cancer immunotherapy (EICCI) Francisco Martin (26407) Biomedical and clinical sciences Immunology adoptive cell theraphy CAR-T cells TCR-engineered T cells tumor antigens mechanisms of resistance |
| status_str | publishedVersion |
| title | Editorial: Engineered immune cells in cancer immunotherapy (EICCI) |
| title_full | Editorial: Engineered immune cells in cancer immunotherapy (EICCI) |
| title_fullStr | Editorial: Engineered immune cells in cancer immunotherapy (EICCI) |
| title_full_unstemmed | Editorial: Engineered immune cells in cancer immunotherapy (EICCI) |
| title_short | Editorial: Engineered immune cells in cancer immunotherapy (EICCI) |
| title_sort | Editorial: Engineered immune cells in cancer immunotherapy (EICCI) |
| topic | Biomedical and clinical sciences Immunology adoptive cell theraphy CAR-T cells TCR-engineered T cells tumor antigens mechanisms of resistance |